Human Telomerase Reverse Transcriptase (hTERT): Cisplatin-내성 암의 치료를 위한 목적 단백질
Human Telomerase Reverse Transcriptase (hTERT): A Target Molecule for the Treatment of Cisplatin-resistant Tumors
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : Human telomerase reverse transcriptase (hTERT) is a catalytic enzyme that is required for telomerase activity (TA) and cancer progression. Telomerase inhibition or inactivation increases cellular sensitivity to UV irradiation, DNA-damaging agents, the tyrosine kinase inhibitor, imatinib, and pharmacological inhibitors, such as BIBR1532. hTERT is associated with apoptosis. Some patients show drug-resistance during anti-cancer drug treatment and the cancer cell acquire anti-apoptotic mechanism. Therefore, we attempted to study correlation between hTERT and drug-resistance. Methods : To study the correlation between protein level and activity of hTERT and drug-resistance, Western blotting and telomerase repeat amplification protocol (TRAP) assays were performed. To investigate whether hTERT contributes to drug resistance in tumor cells, we transiently decreased hTERT levels using small interfering RNA (siRNA) in T24/R2 cells. Results : hTERT knockdown increased Bax translocation into the mitochondria and cytochrome C release into the cytosol. Caspase inhibitors, especially Z-VAD-FMK, rescued this phenomenon, suggesting that the stability or expression of hTERT might be regulated by caspase activity. Conclusions : These data suggest that hTERT might be a target molecule for drug-resistant tumor therapy. (Korean J Lab Med 2008;28:430-7)
Abstract
Background : Human telomerase reverse transcriptase (hTERT) is a catalytic enzyme that is required for telomerase activity (TA) and cancer progression. Telomerase inhibition or inactivation increases cellular sensitivity to UV irradiation, DNA-damaging agents, the tyrosine kinase inhibitor, imatinib, and pharmacological inhibitors, such as BIBR1532. hTERT is associated with apoptosis. Some patients show drug-resistance during anti-cancer drug treatment and the cancer cell acquire anti-apoptotic mechanism. Therefore, we attempted to study correlation between hTERT and drug-resistance. Methods : To study the correlation between protein level and activity of hTERT and drug-resistance, Western blotting and telomerase repeat amplification protocol (TRAP) assays were performed. To investigate whether hTERT contributes to drug resistance in tumor cells, we transiently decreased hTERT levels using small interfering RNA (siRNA) in T24/R2 cells. Results : hTERT knockdown increased Bax translocation into the mitochondria and cytochrome C release into the cytosol. Caspase inhibitors, especially Z-VAD-FMK, rescued this phenomenon, suggesting that the stability or expression of hTERT might be regulated by caspase activity. Conclusions : These data suggest that hTERT might be a target molecule for drug-resistant tumor therapy. (Korean J Lab Med 2008;28:430-7)
참고문헌 (35)
- Chu G., "Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair", J Biol Chem, 269, pp.787~790 (1994)
- Siddik ZH., "Cisplatin: mode of cytotoxic action and molecular basis of resistance", Oncogene, 22, pp.7265~7279 (2003)
- Roth BJ, "Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world", J Urol, 153, pp.894~900 (1995)
- Ozols RF, "High-dose cisplatin in hypertonic saline", Ann Intern Med, 100, pp.19~24 (1984)
- Hagopian GS, "Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV)", Clin Cancer Res, 5, pp.655~663 (1999)
- Levy MZ, "Telomere end-replication problem and cell aging", J Mol Biol, 225, pp.951~960 (1992)
- Feng J, "The RNA component of human telomerase", Science, 269, pp.1236~1241 (1995)
- Meyerson M, "hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization", Cell, 90, pp.785~795 (1997)
- Nakamura TM, "Telomerase catalytic subunit homologs from fission yeast and human", Science, 277, pp.955~959 (1997)
- Lingner J, "Telomerase and chromosome end maintenance", Curr Opin Genet Dev, 8, pp.226~232 (1998)
- Nugent CI, "The telomerase reverse transcriptase: components and regulation", Genes Dev, 12, pp.1073~1085 (1998)
- Bodnar AG, "Extension of life-span by introduction of telomerase into normal human cells", Science, 279, pp.349~352 (1998)
- Muller M., "Telomerase: its clinical relevance in the diagnosis of bladder cancer", Oncogene, 21, pp.650~655 (2002)
- Heine B, "Non-radioactive measurement of telomerase activity in human bladder cancer, bladder washings, and in urine", J Pathol, 184, pp.71~76 (1998)
- Ito H, "Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer", Clin Cancer Res, 4, pp.2807~2810 (1998)
- Dettlaff-Pokora A, "Schlichtholz B. Telomerase activity in urine sediments as a tool for noninvasive detection of bladder cancer", Cancer Lett, 222, pp.83~88 (2005)
- Wong KK, "Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation", Nat Genet, 26, pp.85~88 (2000)
- Chen Z, "Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells", Cancer Res, 63, pp.5917~5925 (2003)
- Tauchi T, "Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells", Clin Cancer Res, 8, pp.3341~3347 (2002)
- Ward RJ, "Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment", Mol Pharmacol, 68, pp.779~786 (2005)
- Lee ES, "Change of chemosensitivity and cellular characteristics of cisplatinum resistant human bladder cancer cells induced by long-term cisplatinum treatment", Korean J Urol, 39, pp.305~310 (1998)
- Kim JK, "Up-regulation of Bfl-1", A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line, 2004, pp.212, 61~70
- Cho HJ, "Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells", Cancer Lett, 237, pp.56~66 (2006)
- Mandal M, "Bcl-2 modulates telomerase activity", J Biol Chem, 272, pp.14183~14187 (1997)
- Melissourgos N, "Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker", Urology, 62, pp.362~367 (2003)
- Zou L, "shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity", Cancer Chemother Pharmacol, 57, pp.328~334 (2006)
- Herbert B, "Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death", Proc Natl Acad Sci U S A, 96, pp.14276~14281 (1999)
- White LK, "Telomerase inhibitors", Trends Biotechnol, pp.114~120 (2001)
- Hahn WC, "Inhibition of telomerase limits the growth of human cancer cells", Nat Med, 5, pp.1164~1170 (1999)
- Schindler A, "Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro", Int J Oncol, 19, pp.25~30 (2001)
- Damm K, "A highly selective telomerase inhibitor limiting human cancer cell proliferation", EMBO J, 20, pp.6958~6968 (2001)
- Kondo Y, "Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component", Oncogene, 19, pp.2205~2211 (2000)
- Koga S, "Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA", Gene Ther, 8, pp.654~658 (2001)
- Saretzki G, "Ribozymemediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells", Cancer Gene Ther, 8, pp.827~834 (2001)
- Cao Y, "TERT regulates cell survival independent of telomerase enzymatic activity", Oncogene, 21, pp.3130~3138 (2002)